Tag Archives: Imbruvica

Patients lose, lawyers win, as AbbVie does deal with Amgen to delay Humira biosim.

The News: Amgen Inc. (Thousand Oaks CA) has agreed to delay the US launch of its FDA-approved biosimilar version of AbbVie Inc.’s (North Chicago) Humira (adalimumab) until 2023, under a… Read more »

Johnson & Johnson Tumbles as Pfizer Set to Launch Remicade Biosimilar; Solid 3rd Quarter Doesn’t Quell Market’s Overreaction

Thriving pharmaceutical sales drove stellar quarterly results for Johnson & Johnson (New Brunswick NJ), but the company’s shares fell 3% so far this week on worries that its smash hit,… Read more »